A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Cisplatin; Docetaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 13 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 10 Jun 2017 Biomarkers information updated